Literature DB >> 12956205

Efficacy and safety of itraconazole use in children.

Aditya K Gupta1, Elizabeth A Cooper, Gabriele Ginter.   

Abstract

Current dosing regimens for itraconazole are effective, safe, and versatile for use in superficial fungal infections in children, particularly tinea capitis. Good efficacy rates have been noted in both Trichophyton and Microsporum tinea capitis infections. Itraconazole has a high affinity for keratin, and accumulates to high levels at the site of superficial fungal infections. A pulse regimen may be chosen over continuous dosing, because the accumulation persists after dosing of itraconazole has been stopped. An oral solution of itraconazole is available, and may be more convenient for children who cannot swallow capsules. The oral solution also produces good rates of efficacy, but may be associated with a somewhat higher potential for gastrointestinal adverse events than the capsules. The range of adverse events noted with itraconazole capsules or oral solution use in children is similar to the range in adults. Events are generally mild and transient. Attention must be taken to note any medications that the child is using, because itraconazole is associated with a range of potential drug interactions. This safety of use, in combination with itraconazole's wide antifungal spectrum and pharmacokinetic properties, which allow for shorter dosing regimens, may make itraconazole a suitable alternative to griseofulvin for pediatric superficial fungal infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12956205     DOI: 10.1016/s0733-8635(03)00030-5

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  7 in total

Review 1.  Recurrent tinea versicolor: treatment with itraconazole or fluconazole?

Authors:  Anastasia Pantazidou; Marc Tebruegge
Journal:  Arch Dis Child       Date:  2007-11       Impact factor: 3.791

2.  Formulation and evaluation of itraconazole liposomes for Hedgehog pathway inhibition.

Authors:  Jennifer R Pace; Rajan Jog; Diane J Burgess; M Kyle Hadden
Journal:  J Liposome Res       Date:  2019-10-02       Impact factor: 3.648

Review 3.  Antifungal therapy in children: an update.

Authors:  Valerio Cecinati; Chiara Guastadisegni; Fabio Giovanni Russo; Letizia Pomponia Brescia
Journal:  Eur J Pediatr       Date:  2012-06-01       Impact factor: 3.183

4.  Antifungal agents in current pediatric practice.

Authors:  Cecinati Valerio; Teresa Perillo; Letizia Brescia; Fabio Giovanni Russo
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

Review 5.  Update in antifungal therapy of dermatophytosis.

Authors:  Aditya K Gupta; Elizabeth A Cooper
Journal:  Mycopathologia       Date:  2008-05-14       Impact factor: 2.574

6.  Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2015-04-15

Review 7.  Efficacy and safety of itraconazole use in infants.

Authors:  Shuang Chen; Kai-Yi Sun; Xiao-Wei Feng; Xin Ran; Jebina Lama; Yu-Ping Ran
Journal:  World J Pediatr       Date:  2016-06-10       Impact factor: 9.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.